Everything below concerns peptide analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
== Criteria == While proteomic methods identified many novel proteins that potentially might be adhesome components they cannot be regarded as adhesome components until they are validated to fulfill the following criteria: 1. they localize to a cell adhesion structure such as focal adhesion or adherens junction. 2. they directly interact with one of the core adhesome components, such as integrin, cadherin or catenins AND/OR their knockdown has a clear effect on cell adhesion.
In 2008, Guinness World Records awarded Half-Life 2 the records for "Highest-rated Shooter by PC Gamer" and "First game to feature a gravity gun". In 2009, Game Informer named Half-Life 2 the fifth-best game, writing that "Valve redefined the way first-person shooters were created". Half-Life 2 was selected by readers of The Guardian as the best game of the decade, with particular praise for the environment design. The Guardian journalist Keith Stuart wrote that it "pushed the envelope for the genre, and set a new high watermark for FPS narrative". Half-Life 2 won Crispy Gamer's Game of the Decade tournament style poll. It also won Reviews on the Run's, IGN's Best Game of the Decade and Spike Video Game Awards 2012 Game of the Decade. In December 2021, IGN named Half-Life 2 the ninth-best game of all time.
Actinides seem to be a little less hard than lanthanides, probably due to a longer spatial extent of 5f atomic orbitals with respect to 4f ones, then a selective separation is possible thanks to ligands bearing soft donors such as nitrogen and sulfur atoms, by a different bonding nature compared to hard donors. Despite the potential separation of actinides, a direct extraction from the PUREX raffinate is very hard, due to the presence of many other interfering species in the feed such as activation and fission products. In this perspective, advanced separation processes involving very selective extracting agents are required to achieve an efficient partitioning for the following transmutation process. To sum up, knowledge of hydration, acid-base interactions, kinetics and thermodynamic stabilities and speciation of actinide and lanthanide ions with ligands is of great value to understand a solvent extraction process and to design new and promising extracting agents.
=== Energy === In July 2018, Minister Rickford tabled Bill 2: Urgent Priorities Act, which received Royal Assent in the same month. The first session of the 42nd Legislature was on July 11 and Bill 2, which passed into law on July 25, was the Ford Government's first piece of legislation. Bill 2—an omnibus bill—was "criticized by both "business groups and unions". It legislated an end to the strike between York University and Canadian Union of Public Employees (CUPE), cancelled the White Pines Wind Project wind farm contract, and gave Ontario government "veto power over compensation at Hydro One." In December 2025, Ford and New York governor Kathy Hochul signed a memorandum of understanding which makes the New York Power Authority and Ontario Power Generation work together on advancing nuclear energy technology. In July 2026, Ford and Alberta premier Danielle Smith proposed an oil pipeline from Alberta to Sarnia, Ontario.
Sources: en.wikipedia.org
HBTU activates carboxylic acids by forming a stabilized HOBt (Hydroxybenzotriazole) leaving group. The activated intermediate species attacked by the amine during aminolysis is the HOBt ester. To create the HOBt ester, the carboxyl group of the acid attacks the imide carbonyl carbon of HBTU. Subsequently, the displaced anionic benzotriazole N-oxide attacks of the acid carbonyl, giving the tetramethyl urea byproduct and the activated ester. Aminolysis displaces the benzotriazole N-oxide to form the desired amide.
Alcohol is one of the oldest recreational drugs. The word "Alcohol" originates from the Arabic word al-kuhul, which refers to a fine metallic powder that was used to paint the eyelids darker. Alcoholic beverages have been produced since the Neolithic period, as early as 7000 BC in China. Alcohol was brewed as early as 7,000 to 6,650 BCE in northern China. The earliest evidence of winemaking was dated at 6,000 to 5,800 BCE in Georgia in the South Caucasus. Beer was likely brewed from barley as early as 13,000 years ago in the Middle East. Pliny the Elder wrote about the golden age of winemaking in Rome, the 2nd century BCE (200–100 BCE), when vineyards were planted.
6 January – The Prime Minister responds to X owner Elon Musk and others he accuses of "spreading lies and misinformation" over grooming gangs. Starmer tells reporters that these online debates have now "crossed a line", resulting in threats against MPs, including Safeguarding Minister Jess Phillips. MPs debate an online petition calling for a re-run of the 2024 general election in Westminster Hall, a secondary debating chamber. Treasury Minister Tulip Siddiq refers herself to the Independent Adviser on Ministers' Interests after controversy over her links to her aunt's political movement in Bangladesh. Justin Welby's tenure as Archbishop of Canterbury comes to an end following his resignation in November 2024. Archbishop of York Stephen Cottrell assumes temporary charge of the Church of England from the following day. 7 January – Minister Jess Phillips says Elon Musk is putting her in danger with misinformation about grooming gangs. 8 January – MPs vote 364–111 against a Conservative proposal to require the UK government to establish an inquiry into grooming gangs. The Liberal Democrats are ordered to pay £14,000 to Natalie Bird, a former parliamentary candidate who says she was driven out of the party and barred from standing as an MP over her gender-critical views. Sir Oliver Robbins is appointed Permanent Secretary to the Foreign Office, succeeding Sir Philip Barton. Patrick Harvie, the co-leader of the Scottish Greens, is to take time off from the Scottish Parliament because of a medical procedure.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.